Soft Chewable Antiparasitic Tablet With Praziquantel Taste Masking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compositions for treating parasitic infestations in small animals do not effectively mask the bitter taste of active ingredients like praziquantel, limiting their palatability and efficacy.
Innovation Solution
A pharmaceutical composition comprising fluralaner, moxidectin, and praziquantel in a soft chewable tablet form, utilizing bitter taste receptor blockers such as adenosine 5'-monophosphate and monosodium glutamate, along with flavor enhancers and excipients, to mask the bitter taste and improve palatability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If praziquantel is used as an active ingredient in the composition, then the treatment of parasitic infestations is effective, but the bitter taste of praziquantel reduces palatability and animal acceptance
Solution Approach 1:
The patent introduces bitter taste blockers (adensosine 5'-monophosphate and monosodium glutamate) as intermediary substances that mediate between the bitter-tasting praziquantel and the animal's taste receptors. These blockers specifically inhibit the binding of praziquantel to bitter taste receptors, allowing the active ingredient to maintain its therapeutic effect while preventing the unpleasant bitter taste sensation in animals
Solution Approach 2:
The patent changes the chemical parameters of the composition by incorporating specific bitter taste blockers that alter the taste profile. By adding adenosine 5'-monophosphate and monosodium glutamate at optimized concentrations (0.1-5% and 0.1-3% respectively), the composition transforms from bitter to palatable while maintaining the pharmacological activity of praziquantel
2Adaptability or versatility
If multiple active ingredients (fluralaner, moxidectin, praziquantel) are combined in one composition, then comprehensive parasitic coverage is achieved, but the complexity of formulation and taste masking increases
Solution Approach 1:
The patent merges multiple active ingredients with different mechanisms of action (fluralaner for ectoparasites, moxidectin for endoparasites, and praziquantel for tapeworms) into a single soft chewable tablet formulation. By combining these ingredients with bitter taste blockers and flavoring agents in one integrated formulation, the patent achieves broad-spectrum parasitic coverage while maintaining simplicity in administration
Solution Approach 2:
The patent creates a universal composition that addresses multiple parasitic infestations simultaneously through a single administration. The formulation is designed to be multi-functional, treating ectoparasites, endoparasites, and tapeworms in one tablet, thereby simplifying the treatment regimen despite the complexity of covering multiple parasite types
Data Source
AI summary
The present invention is aimed at a pharmaceutical formulation or composition and a method of manufacture or production thereof, wherein the pharmaceutical composition includes fluralaner, moxidectin and praziquantel for the treatment of parasitic infestations in animals, wherein the composition may be in tablet form, more particularly as a chewable tablet and more preferably as a soft chewable tablet that manages to mask the bitter taste of the active ingredient praziquantel based on an association of bitter taste receptor blockers.